When Arcturus presented its mRNA vaccine candidate to Recipharm, it was at the stage of a frozen product, a ready-to-administer sterile injectable for Phase I and II clinical trials.
The inherent cryogenic logistics and storage costs associated with mRNA vaccines, as well as their intended markets created a challenge for Phase III clinical trial and commercialisation. Recipharm supported Arcturus in mitigating these challenges, providing a solution that met their supply needs within the strictest timelines.